Meet us at the first DxPx – Diagnostics Partnering conference in Dusseldorf on November 18th Sara Fröjdö, Partnership Manager at BIOASTER, will be present at the 1st DxPx Diagnostics Partnering...
Don’t forget to register to the next I4ID 2019 congress! Registrations to the 3rd Immunotherapies & Innovation for Infectious Diseases (I4ID2019) are still opened. The congress will be held on...
A new publication has been released this summer in Metabolomics. Entitled “Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease”,...
BIOASTER announces a collaboration with Exeliom Biosciences, a leading biotech in the developement of innovative microbiome-based therapies, located in Paris and Dijon, France. The aim of the partnership is to...
7th Annual Single Cell Analysis Congress 07 – 08 November 2019, London, UK Microfluidics BIOASTER will be attending the 7th Annual Single Cell Analysis Congress 07 – 08 November 2019,...
BIOASTER, the Technology Research Institute (TRI) gives itself the means to develop new partnerships with American foundations invested in the fight against infectious diseases. The BIOASTER Foundation received an “Equivalency...
This video is intended to explain to everyone what the #biofilm is and why it is a key element to improve research, in addition, in the fight against #chronicDiseases and...
BIOASTER will participate to the next FLI (France Life Imaging) day on September 26th at Orsay. This 5th edition will be dedicated to lastest breakthrough in infectious & inflammation imaging....
Dynamiser la recherche sur le microbiote. Deux lauréats du Programme des Investissements d’Avenir (PIA), #Metagenopolis @INRA (démonstrateur pré-industriel, Lauréat 2012) et @BIOASTER (L’Institut de Recherche Technologique en microbiologie, Lauréat 2012),...
BIOASTER announces the kick off a new IMI project “GNA NOW” (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI),...
BIOASTER announced the signature of a collaboration agreement with Pherecydes Pharma, a French Biotechnology company, with the objective of discovering lytic bacteriophages, to be developed into a pharmaceutical solution to...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
